Treatment of patients with tumor/treatment-related hypothalamic obesity in the first two years following surgical treatment or radiotherapy
Abstract Survivors of sellar/suprasellar tumors involving hypothalamic structures face a risk of impaired quality of life, including tumor- and/or treatment-related hypothalamic obesity (TTR-HO) defined as abnormal weight gain resulting in severe persistent obesity due to physical, tumor- and/or tre...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-85262-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594863179169792 |
|---|---|
| author | Hermann L. Müller Julian Witte Bastian Surmann Manuel Batram Kylie Braegelmann Mathias Flume Julia Beckhaus Nicolas Touchot Carsten Friedrich |
| author_facet | Hermann L. Müller Julian Witte Bastian Surmann Manuel Batram Kylie Braegelmann Mathias Flume Julia Beckhaus Nicolas Touchot Carsten Friedrich |
| author_sort | Hermann L. Müller |
| collection | DOAJ |
| description | Abstract Survivors of sellar/suprasellar tumors involving hypothalamic structures face a risk of impaired quality of life, including tumor- and/or treatment-related hypothalamic obesity (TTR-HO) defined as abnormal weight gain resulting in severe persistent obesity due to physical, tumor- and/or treatment related damage of the hypothalamus. We analyze German claims data to better understand treatment pathways for patients living TTR-HO during the two years following the index surgical treatment. A database algorithm identified patients with TTR-HO in a representative German payer claims database between 2010 and 2021 (n = 5.42 million patients). Claims from 37 patients with TTR-HO were analyzed on a quarterly basis over 2 years. The analysis considered inpatient, outpatient, and prescription data. In the follow-up period, patients with TTR-HO are hospitalized 3.68 times on average; 37% of hospitalizations in year 1 and 31% in year 2 are due to TTR-HO. On average, patients see a general practitioner 12.27 times and various specialists 20.45 times. The need for complex neuroendocrine therapy develops quickly, with most patients having 2–3 neuroendocrine prescriptions in any given quarter. The management of patients with TTR-HO requires frequent inpatient and outpatient visits for tumor follow-up and management of incident comorbidities, and most patients with TTR-HO require intense polytherapy. |
| format | Article |
| id | doaj-art-d6c847b7d72a4b9989a68e8efa268081 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-d6c847b7d72a4b9989a68e8efa2680812025-01-19T12:19:23ZengNature PortfolioScientific Reports2045-23222025-01-011511910.1038/s41598-025-85262-1Treatment of patients with tumor/treatment-related hypothalamic obesity in the first two years following surgical treatment or radiotherapyHermann L. Müller0Julian Witte1Bastian Surmann2Manuel Batram3Kylie Braegelmann4Mathias Flume5Julia Beckhaus6Nicolas Touchot7Carsten Friedrich8Department of Pediatrics and Pediatric Hematology/Oncology, University Children’s Hospital, Carl Von Ossietzky UniversitätVandage GmbHVandage GmbHVandage GmbHVandage GmbHGene Access GmbHDepartment of Pediatrics and Pediatric Hematology/Oncology, University Children’s Hospital, Carl Von Ossietzky UniversitätRhythm PharmaceuticalsDepartment of Pediatrics and Pediatric Hematology/Oncology, University Children’s Hospital, Carl Von Ossietzky UniversitätAbstract Survivors of sellar/suprasellar tumors involving hypothalamic structures face a risk of impaired quality of life, including tumor- and/or treatment-related hypothalamic obesity (TTR-HO) defined as abnormal weight gain resulting in severe persistent obesity due to physical, tumor- and/or treatment related damage of the hypothalamus. We analyze German claims data to better understand treatment pathways for patients living TTR-HO during the two years following the index surgical treatment. A database algorithm identified patients with TTR-HO in a representative German payer claims database between 2010 and 2021 (n = 5.42 million patients). Claims from 37 patients with TTR-HO were analyzed on a quarterly basis over 2 years. The analysis considered inpatient, outpatient, and prescription data. In the follow-up period, patients with TTR-HO are hospitalized 3.68 times on average; 37% of hospitalizations in year 1 and 31% in year 2 are due to TTR-HO. On average, patients see a general practitioner 12.27 times and various specialists 20.45 times. The need for complex neuroendocrine therapy develops quickly, with most patients having 2–3 neuroendocrine prescriptions in any given quarter. The management of patients with TTR-HO requires frequent inpatient and outpatient visits for tumor follow-up and management of incident comorbidities, and most patients with TTR-HO require intense polytherapy.https://doi.org/10.1038/s41598-025-85262-1Hypothalamic obesityTumor/treatment related HORare sellar/suprasellar tumorsCraniopharyngiomaEndocrinology |
| spellingShingle | Hermann L. Müller Julian Witte Bastian Surmann Manuel Batram Kylie Braegelmann Mathias Flume Julia Beckhaus Nicolas Touchot Carsten Friedrich Treatment of patients with tumor/treatment-related hypothalamic obesity in the first two years following surgical treatment or radiotherapy Scientific Reports Hypothalamic obesity Tumor/treatment related HO Rare sellar/suprasellar tumors Craniopharyngioma Endocrinology |
| title | Treatment of patients with tumor/treatment-related hypothalamic obesity in the first two years following surgical treatment or radiotherapy |
| title_full | Treatment of patients with tumor/treatment-related hypothalamic obesity in the first two years following surgical treatment or radiotherapy |
| title_fullStr | Treatment of patients with tumor/treatment-related hypothalamic obesity in the first two years following surgical treatment or radiotherapy |
| title_full_unstemmed | Treatment of patients with tumor/treatment-related hypothalamic obesity in the first two years following surgical treatment or radiotherapy |
| title_short | Treatment of patients with tumor/treatment-related hypothalamic obesity in the first two years following surgical treatment or radiotherapy |
| title_sort | treatment of patients with tumor treatment related hypothalamic obesity in the first two years following surgical treatment or radiotherapy |
| topic | Hypothalamic obesity Tumor/treatment related HO Rare sellar/suprasellar tumors Craniopharyngioma Endocrinology |
| url | https://doi.org/10.1038/s41598-025-85262-1 |
| work_keys_str_mv | AT hermannlmuller treatmentofpatientswithtumortreatmentrelatedhypothalamicobesityinthefirsttwoyearsfollowingsurgicaltreatmentorradiotherapy AT julianwitte treatmentofpatientswithtumortreatmentrelatedhypothalamicobesityinthefirsttwoyearsfollowingsurgicaltreatmentorradiotherapy AT bastiansurmann treatmentofpatientswithtumortreatmentrelatedhypothalamicobesityinthefirsttwoyearsfollowingsurgicaltreatmentorradiotherapy AT manuelbatram treatmentofpatientswithtumortreatmentrelatedhypothalamicobesityinthefirsttwoyearsfollowingsurgicaltreatmentorradiotherapy AT kyliebraegelmann treatmentofpatientswithtumortreatmentrelatedhypothalamicobesityinthefirsttwoyearsfollowingsurgicaltreatmentorradiotherapy AT mathiasflume treatmentofpatientswithtumortreatmentrelatedhypothalamicobesityinthefirsttwoyearsfollowingsurgicaltreatmentorradiotherapy AT juliabeckhaus treatmentofpatientswithtumortreatmentrelatedhypothalamicobesityinthefirsttwoyearsfollowingsurgicaltreatmentorradiotherapy AT nicolastouchot treatmentofpatientswithtumortreatmentrelatedhypothalamicobesityinthefirsttwoyearsfollowingsurgicaltreatmentorradiotherapy AT carstenfriedrich treatmentofpatientswithtumortreatmentrelatedhypothalamicobesityinthefirsttwoyearsfollowingsurgicaltreatmentorradiotherapy |